Averin Capital Acquisition, a blank check company targeting health and life sciences, filed on Friday with the SEC to raise up to $250 million in an initial public offering.
The New York, NY-based company plans to raise $250 million by offering 25 million units at a price of $10. Each unit consists of one share of common stock and one-sixth of one warrant, exercisable at $11.50.
Averin Capital Acquisition is set to be led by Chairman and CEO David Berry, who co-founded Averin Capital in 2023, and has served as its Managing Partner since. He currently serves as Chairman of Osler Diagnostics, and as a Director at Oaktree Acquisition III Life Sciences, Hologen, Biolinq, and Salma Health. He is joined by CFO Alex Lau, who has served as the Partner and Head of Operations at Averin Capital since February 2025.
The New York, NY-based company was founded in 2025 and plans to list on the Nasdaq under the symbol ACAAU. Averin Capital Acquisition filed confidentially on November 17, 2025. Deutsche Bank is the sole bookrunner on the deal.
